NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $3.74 +0.15 (+4.18%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.75 +0.01 (+0.29%) As of 08/22/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioLineRx Stock (NASDAQ:BLRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioLineRx alerts:Sign Up Key Stats Today's Range$3.52▼$3.9250-Day Range$3.56▼$4.9252-Week Range$2.30▼$30.34Volume51,310 shsAverage Volume38,228 shsMarket Capitalization$15.93 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingStrong Buy Company Overview BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Read More BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreBLRX MarketRank™: BioLineRx scored higher than 68% of companies evaluated by MarketBeat, and ranked 337th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingBioLineRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioLineRx has only been the subject of 2 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.93% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 12.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.93% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 12.28%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.64 News SentimentBioLineRx has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioLineRx this week, compared to 1 article on an average week.MarketBeat Follows17 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 1,600% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address BLRX Stock News HeadlinesResearch Analysts Issue Forecasts for BioLineRx Q3 EarningsAugust 19, 2025 | americanbankingnews.comBioLineRx (NASDAQ:BLRX) Stock Passes Above 200 Day Moving Average After Earnings MissAugust 17, 2025 | americanbankingnews.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.August 23 at 2:00 AM | Weiss Ratings (Ad)BLRX: ASCO Poster & AbstractAugust 16, 2025 | finance.yahoo.comBioLineRx Ltd.: BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deBioLineRx Ltd. (BLRX) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comBioLineRx reports Q2 EPS 0c vs. 0c last yearAugust 14, 2025 | msn.comBioLineRx Reports Q2 2025 Financials and Strategic UpdatesAugust 14, 2025 | msn.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $8.56 at the beginning of 2025. Since then, BLRX shares have decreased by 56.3% and is now trading at $3.74. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Thursday, August, 14th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.65. The biotechnology company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.66 million. BioLineRx had a negative trailing twelve-month return on equity of 49.74% and a negative net margin of 45.34%. Read the conference call transcript. When did BioLineRx's stock split? Shares of BioLineRx reverse split on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are BioLineRx's major shareholders? Top institutional shareholders of BioLineRx include Group One Trading LLC. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA). Company Calendar Last Earnings8/14/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees40Year FoundedN/APrice Target and Rating Average Price Target for BioLineRx$26.00 High Price Target$26.00 Low Price Target$26.00 Potential Upside/Downside+595.2%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.22 million Net Margins-45.34% Pretax Margin-45.34% Return on Equity-49.74% Return on Assets-17.54% Debt Debt-to-Equity Ratio0.33 Current Ratio2.06 Quick Ratio2.04 Sales & Book Value Annual Sales$28.94 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book0.79Miscellaneous Outstanding Shares4,260,000Free Float4,216,000Market Cap$15.93 million OptionableOptionable Beta1.15 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BLRX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.